Zobrazeno 1 - 9
of 9
pro vyhledávání: '"K. A. Zhbanov"'
Autor:
N. N. Pakhtusov, A. O. Yusupova, K. A. Zhbanov, A. A. Shchedrygina, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 6, Pp 630-637 (2023)
Aim. To study the levels of fibrosis markers in patients with stable coronary artery disease (CAD) and various types of coronary artery (CA) lesions (obstructive and non-obstructive), to identify possible differences for diagnosing the types of coron
Externí odkaz:
https://doaj.org/article/50de31acbeaa49af9d1f6f4b98918670
Autor:
K. A. Zhbanov, E. Yu. Salakheeva, I. Ya. Sokolova, E. A. Zheleznykh, V. Yu. Zektser, E. V. Privalova, Yu. N. Belenkov, A. A. Shchendrygina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 5, Pp 522-529 (2022)
Neuregulin-1β (NRG-1) is an emerging biomarker of heart failure (HF). The mechanisms of its action in HF patients are yet to be investigated. Cardioprotective and anti-inflammatory effects of NRG-1 have been reported.Aim. To assess NRG-1 levels in H
Externí odkaz:
https://doaj.org/article/fac330f609e14930a2d5b72fce06956d
Autor:
E. Yu. Salakheeva, I. Ya. Sokolova, O. V. Lyapidevskaya, K. A. Zhbanov, S. A. Tsatsurova, N. I. Kanevskiy, V. O. Stebakova, E. V. Privalova, I. S. Ilgisonis, Yu. N. Belenkov, A. A. Shchendrygina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 18, Iss 4, Pp 385-392 (2022)
Aim. To assess the structure and performance of left atrium (LA) before and after 3 cycles of anticancer treatment in lymphoma patients, as well as the incidences of supraventricular arrhythmia (SVA) and the levels of biomarkers of inflammation.Mater
Externí odkaz:
https://doaj.org/article/9240aeffbbdc46338439833b544c3365
Autor:
K. A. Zhbanov, A. A. Shchendrygina, E. A. Zheleznykh, E. V. Privalova, A. Y. Suvorov, A. S. Ablyametova, N. F. Fuksman, E. Yu. Salakheeva, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 6, Pp 853-859 (2022)
Aim. To determine the median levels of neuregulin-1 (NRG-1; endothelium-derived growth factor and the natural agonist of the ERBB3 and ERBB4 receptors) NRG-1 in healthy volunteers and to study the associations of NRG-1 levels with gender and age.Mate
Externí odkaz:
https://doaj.org/article/0ce5df5ad42647ef804ef075ba009ed4
Autor:
A. A. Shchendrygina, K. A. Zhbanov, E. V. Privalova, A. O. Yusupova, Yu. A. Danilogorskaya, E. Yu. Salakheeva, I. Ya. Sokolova, S. A. Tsatsurova, A. A. Ageeva, Yu. N. Belenkov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 3, Pp 476-483 (2021)
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is
Externí odkaz:
https://doaj.org/article/c7ce94c4d13c4fb0b9597a86d8501960
Autor:
E. Yu. Salakheeva, A. A. Shchendrygina, I. Ya. Sokolova, K. A. Zhbanov, S. A. Tsatsurova, N. I. Kanevskiy, Yu. N. Muzychenko, S. A. Kardanova, V. O. Stebakova, E. V. Privalova, T. Yu. Kulagina, O. A. Bulkina, I. S. Ilgisonis, Yu. N. Belenkov
Publikováno v:
Clinical Medicine (Russian Journal). 101:55-62
Aim. To assess the dynamics of functional changes in the left atrium (LA) in patients with lymphoproliferative diseases (LPD) before polychemotherapy (PCT), during treatment, after 6 courses of treatment, and the frequency of supraventricular arrhyth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbfbe0e4189f3de8a38bee74e4d78f83
https://doi.org/10.30629/0023-2149-2023-101-1-55-62
https://doi.org/10.30629/0023-2149-2023-101-1-55-62
Autor:
K. A. Zhbanov, A. A. Shchendrygina, E. Yu. Salakheeva, I. Ya. Sokolova, A. A. Agadzhanyan, E. A. Zheleznykh, V. Yu. Zektser, E. V. Privalova, Yu. N. Belenkov
Publikováno v:
Kardiologiia. 62:3-8
Aim To determine the neuregulin-1β concentration in patients with chronic heart failure with preserved ejection fraction (HFpEF) and the association of this biomarker with the functional status of patients, echocardiographic parameters of the struct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc8060fb0d33907874dc0485c00eda8
https://doi.org/10.18087/cardio.2022.9.n2241
https://doi.org/10.18087/cardio.2022.9.n2241
Autor:
Yu A Danilogorskaya, Yu N Belenkov, I. Ya. Sokolova, E. Yu. Salakheeva, S. A. Tsatsurova, A A Shchendrygina, A. A. Ageeva, K. A. Zhbanov, E. V. Privalova, A. O. Yusupova
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 3, Pp 476-483 (2021)
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a437227612ae7820537df786f1db790b
https://doi.org/10.20996/1819-6446-2021-05-01
https://doi.org/10.20996/1819-6446-2021-05-01
Autor:
A A Shchendrigina, M G Mnatsakanyan, Yu N Belenkov, A H Bytdaeva, Yu I Naymann, Yu A Danilogorskaya, A O Iusupova, V Yu Zektser, N V Khabarova, E S Starostina, E A Zheleznykh, A Yu Suvorov, O V Lyapidevskaya, E. V. Privalova, K. A. Zhbanov
Publikováno v:
Kardiologiia. 60(11)
Chronic heart failure (CHF) with preserved ejection fraction (CHFpEF) is an unsolved, socially relevant challenge since it is associated with a high level of morbidity and mortality. Early markers for this pathology are unavailable, and therapeutic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8781fbf3028bf206408f322a927d5892
https://pubmed.ncbi.nlm.nih.gov/33487159
https://pubmed.ncbi.nlm.nih.gov/33487159